Treating substance use and traumatic stress among adolescents: A pilot study

Not Applicable

Completed

• Conditions: post-traumatic stress; substance use; Mental Health - Anxiety; Mental Health - Addiction

• Registration Number: ACTRN12614001018606
• Lead Sponsor: Mental Health and Drug and Alcohol Office (MHDAO)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-09-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

(i) aged between 12-17 years,
(ii) substance use in the past month,
(iii) lifetime exposure to at least one traumatic event,
(iv) partial or full diagnosis of current PTSD.

Exclusion Criteria

(i) recent history of suicide or self-harm,
(ii) chronic psychosis,
(iii) organic or traumatic brain injury, or
(iv) ongoing trauma-related threat or ongoing unsupervised contact with the alleged perpetrator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Acceptability of the COPE-A intervention will be measured using the Youth Client Satisfaction Questionnaire (YCSQ) and the Revised Helping Alliance Questionnaire (Haq-II). [At completion of the COPE-A treatment (i.e. at 16 weeks post-baseline)];Feasibility of the COPE-A treatment will be measured as session attendance and treatment drop out. The therapist will also complete a session checklist at the end of each session to record which components were completed. [At completion of the COPE-A treatment (i.e. at 16 weeks post-baseline)]

Secondary Outcome Measures

Name	Time	Method
Substance use will be measured using the CRAFFT Screening Tool[Assessed at baseline and post-treatment (i.e. at 16 weeks post-baseline)];PTSD symptoms will be measured using the UCLA PTSD-Reaction Index[Assessed at baseline and post-treatment (i.e. at 16 weeks post-baseline)];Psychological distress will be measured using the Kessler-10[Assessed at baseline and post-treatment (i.e. at 16 weeks post-baseline)];Emotional, social, and behavioural functioning will be measured using the Strengths and Difficulties Questionnaire (SDQ)[Assessed at baseline and post-treatment (i.e. at 16 weeks post-baseline)];Aggression will be measured using the Reactive Proactive Aggression Questionnaire and the Olweus Bullying Questionnaire[Assessed at baseline and post-treatment (i.e. at 16 weeks post-baseline)];Sessions will be recorded and reviewed to document therapeutic compliance. [At completion of the COPE-A treatment (i.e. at 16 weeks post-baseline)]